Contact

Office Tel.:

+49 - 731 - 50060080/81

Office Fax:

+49 - 731 - 50060082

Laboratory:

+49 - 731 - 50060083/84/85

Our team

    Marion Schneider, Prof., Dr. rer. nat., focuses on the development of biomarker protocols for immune-based diagnostics in inflammatory diseases. She holds a data base of >20,000 patients with immune phenotypes and cytokine expression patterns, and functional SNPs. Biological materials such as PBMC, plasma, DNA, RNA are archived. Teaching concentrates on practical courses in Immunology, SNP sequencing and ex-vivo modeling of disease states for students in Molecular and Human Medicine.

      Ning Dan, M. Sc. MD, studies patients with pain syndromes and metabolic dysfunction including diabetes mellitus II, and sepsis for SNP polymorphisms and macrophage activation.

      • Profilbild von Prof. Dr. med. Manfred Weiß

        Prof. Dr. med. Manfred Weiß

        Oberarzt, Facharzt für Anästhesiologie, Zusatzbezeichnungen: Notfallmedizin, leitender Notarzt, spezielle Intensivmedizin, spezielle Schmerztherapie,  Palliativmedizin

      Manfred Weiss, Prof. Dr. med. MA, cooperates on patients with leukopenia and the beneficial effects by G-CSF.

        Karl Föhr, PD, Dr. rer. nat., runs an electrophysiological lab, performing patch-clamp recordings at ligand- and voltage-gated ion channels using primary cells (e.g. neurons) or heterologous expression systems (HEK-293).  

          Li, Chen, M. Sc., PhD student (biol. hum.), studiesimmune macrophage subclassification, functional phagocytosis and entosis assays, by video microscopy, PCR of miRNA species related to chronic inflammation.

            Scheiber, Christian, M. Sc., PhD student (Mol Med.), works on isolated microparticles and exosomes from CSF of psychiatric patients and patients with subarachnoidal bleeding. His virus diagnostics are based on miRNA signatures.

              Stefan Baeder, (engineer), is responsible for confocal scanning microscopy and set up of flow assay for microscopical devices including video microscopy and migration of inflammatory cells.

                Hans Klein, is our guest scientist as part of the EU project MOOD STRATIFICATION.

                  Marla Teufel, does your federal voluntary service in our team.

                  Diseases

                  Hemophagocytic Lymphohistiocytosis

                  References:

                  Lin, M, Park, S,  Hayden, A, Giustini, D, Trinkaus, M, Pudek, M, Mattman, A, Schneider, M, and Chen, LYC. Clinical utility of soluble interleukin-2 receptor in hemophagocytic syndromes: a systematic scoping review. Annals of Hematology 96 (2017) 1241-1251

                  Janka, G, Schneider, EM. Hämophagozytische Lymphohistiozytosen. In: Gadner H, Gaedicke G, Niemeyer C, Ritter J (eds). Pädiatrische Hämatologie und Onkologie. Springer Medizin Verlag Heidelbert; 2006. ISBN 10-3-540-03702-0

                  Titze, U., G. Janka, E.M. Schneider, F. Prall, D. Haffner, and C.F. Classen. 2009. Hemophagocytic lymphohistiocytosis and Kawasaki disease: combined manifestation and differential diagnosis. Pediatr Blood Cancer. 2009; 53:493-5.

                  Woehrle T, Du W, Goetz A, Hsu H, Joos T, Weiss M, Bauer U, Brueckner U, Schneider EM. Pathogen specific cytokine release reveals an effect of TLR2 Arg753Gln during Candida sepsis in humans. Cytokine 2007,

                  Edner J, Rudd E, Zheng C, Dahlander A, Eksborg S, Schneider EM, Edner A, Henter JI. Severe bacteria-associated hemophagocytic lymphohistiocytosis in an extremely premature infant. Acta Paediatr 2007, 96:1703-1706.

                  Horne A, Zheng C, Lorenz I, Lofstedt M, Montgomery SM, Janka G, Henter JI, Marion Schneider E. Subtyping of natural killer cell cytotoxicity deficiencies in haemophagocytic lymphohistocytosis provides therapeutic guidance. Br J Haematol 2005, 129:658-666.

                  Janka GE, Schneider EM. Modern management of children with haemophagocytic lymphohistiocytosis. Brit. J. Hematol 2004, 124: 4-14.

                  Schneider, EM. Bullfight without killer weapons: interferon rules pathology in HLH. Blood 2004, 104(3): 600 – 601.

                  zur Stadt U, Kabisch H, Janka G, Schneider EM. Rapid LightCycler assay for screening of the codon 374 Trp->stop mutation in patients and families with hemophagocytic lymphohistiocytosis (FHLH). Med Pediatr Oncol 2003; 41(1): 26-9

                  Schneider EM, Lorenz I, Muller-Rosenberger M, Steinbach G, Kron M, Janka-Schaub GE. Hemophagocytic lymphohistiocytosis is associated with deficiencies of cellular cytolysis but normal expression of transcripts relevant to killer-cell-induced apoptosis. Blood 2002;100(8):2891-8.

                  zur Stadt U, Pruggmayer M, Jung H, Henter JI, Schneider EM, Kabisch H,Janka G. Prenatal diagnosis of perforin gene mutations in familial hemophagocytic lymphohistiocytosis (FHLH). Prenat Diagn 2002;22(1):80-1

                  Clementi, R. zur Stadt, U., Savoldi, G., Varoitto, S., Conter, V., De Fusco, C. Notarangelo, U.L., Schneider, E. M., Klersy, C., Janka, G., Danesino, C., Arico, M. Six novel mutations in the PRF1 gene in children with haemophagocytic lymphohistiocytosis. J Med Genet 2001; 38(9):643-6

                  Durken M, Horstmann M, Bieling P, Erttmann R, Kabisch H, Loliger C, Schneider EM, Hellwege HH, Kruger W, Kroger N, Zander AR, Janka GE. Improved outcome in haemophagocytic lymphohistiocytosis after bone marrow transplantation from related and unrelated donors: a single-centre experience of 12 patients. Br.J.Haematol. 1999;106(4):1052-1058.

                  Dufourcq-Lagelouse R, Jabado N, Le Deist F, Stephan JL, Souillet G, Bruin M, Vilmer E, Schneider M, Janka G, Fischer A,de Saint BG. Linkage of familial hemophagocytic lymphohistiocytosis to 10q21-22 and evidence for heterogeneity. Am.J.Hum.Genet. 1999;64(1):172-179.

                  Janka G, Imashuku S, Elinder G, Schneider EM, Henter JI. Infection-and malignancy-associated Hemophagocytic Syndromes. Hematol.Oncol.Clin.North Am. 1998;12(2):435-444.

                  Durken M, Schneider EM, Blutters-Sawatzki R, Stollmann-Gibbels B, Nessler G, Bretz R, Korholz D, Probst EN, Holsten-Griffin H, Harps E, Zander AR,Janka GE. [Treatment of hemophagocytic lymphohistiocytosis, HLH, with bone marrow transplantation]. Klin.Padiatr. 1998;210(4):180-184.

                  Kusenbach G, Rubben A, Schneider EM, Barker M, Bussing A, Lassay L, Skopnik H,Heiman G. Herpes virus (KSHV) associated Kaposi sarcoma in a 3-year-old child with non-HIV-induced immunodeficiency. Eur.J.Pediatr. 1997;156(6):440-443.

                  Macrophage Activation Syndromes

                  References:

                  Walther P, Bauer A, Wenske N, Catanese A, Garrido D, Schneider EM. (2018) STEM tomography of high-pressure frozen and freeze-substituted cells: a comparison of image stacks obtained at 200 kV or 300 kV. Histochem Cell Biol. 2018 Sep 18. doi: 10.1007/s00418-018-1727-0. [Epub ahead of print]

                  Schneider EM, Flacke, S, Liu, F, Lorenz, MR, Schilling, P, Nass, ME., Foehr, KJ, Huber-Lang, Markus, Weiss, Manfred E. Autophagy and ATP-induced anti-apoptosis in antigen presenting cells (APC) follows the cytokine storm in patients after major trauma Journal of Cell Communication and Signaling. 2011, 5:145-156.

                  Waqas, SF, Hassnain, Hoang, AC, Lin, Y-T, Ampem, G., Azegrouz, H, Balogh, L, Thuróczy, J, Chen, J-C, Gerling, IC, Nam, S, Lim, J-S, Martínez-Ibañez, J, Real, J, Paschke, S, Quillet, R, Ayachi, S, Simonin, F, Schneider, EM, Brinkman, JA, Lamming, DW, Seroogy, CM, Röszer, T. Neuropeptide-FF increases M2 activation and self-renewal of adipose tissue macrophages. J Clin Investigation 2017 in press.

                  Pain Syndromes

                  Under Construction

                  We are sorry for the inconvenience.

                  Trauma, Sepsis, Septic Shock

                  References:

                  Denzinger, M, Staendker, L, Ehlers, K, Schneider, JM, Schulz, T, Hein, T, Wiese, S,  Roecker, A, Gross, R, Muench, J,  Bracht, H, Barth, E, Weiss, M, Georgieff, M,  Schneider, EM. Bioassay for Endothelial Damage Mediators Retrieved by Hemoadsorption, Sci Rep. Sci Rep 9, 14522 (2019) doi:10.1038/s41598-019-50517-1

                  Geistlinger J, Du, W., Groll, J, Liu, F, Hoegel, J, Foehr, KJ, Pasquarelli, A, Schneider, EM. P2RX7 genotype association in severe sepsis identified by a novel Multi-Individual Array for rapid screening and replication of risk SNPs. Clin Chim Acta. 2011. DOI 10.1016/j.caa.2011.05.023.

                  Kriebel F, Wittemann S, Hsu HY, Joos T, Weiss M, Schneider EM. Caspase-3 activation, Bcl-2 contents, and soluble FAS-ligand are not related to the inflammatory marker profile in patients with sepsis and septic shock. Ann N Y Acad Sci 2006, 1090:168-176

                  Major Depression

                  References:

                  Mack, A, Pfeiffer, C, Schneider, EM, Bechter, K. Schizophrenia or Atypical Lupus Erythematosus with Predominant Psychiatric Manifestations over 25 Years: Case Analysis and Review. Front Psychiatry. 2017 Jul 27;8:131. doi: 10.3389/fpsyt.2017.00131. eCollection 2017.

                  Maxeiner HG, Marion Schneider E, Kurfiss ST, Brettschneider J, Tumani H, Bechter K. Cerebrospinal fluid and serum cytokine profiling to detect immune control of infectious and inflammatory neurological and psychiatric diseases. Cytokine 2014. 69:62-7.

                  Malignancies

                  References:

                  Sander, P, Walther, P, Moepps, B, Hinz, M, Mostafa, H, Schaefer, P, Pala, A, Wirtz, CR, Georgieff, M, and Schneider, EM. 2019. Mitophagy-Related Cell Death Mediated by Vacquinol-1 and TRPM7 Blockade in Glioblastoma IV. In: OMERHODZIC, I. & ARNAUTOVIĆ, K. (eds.) Glioma - Contemporary Diagnostics and Therapeutic Approaches. IntechOpen, 81-93.

                  Schneider, EM, Zielberg, D, Aigner, KR, Mostafa, H, Schneider, JM, Paschke, S. Systemic inflammation and immune suppression biomarkers in patients with solid tumors undergoing regional chemotherapy. Deutsche Zeitschrift für Onkologie Deutsche Zeitschrift für Onkologie 2017; 49: 8–14; DOI http://dx.doi.org/10.1055/s-0043-104756

                  Sander, S, Mostafa, H, Soboh, A, Schneider JM, Pala, A, Baron, A-K, Moepps, B, Wirtz, CR, Georgieff, M, Schneider, EM. Vacquinol-1 inducible cell death in glioblastoma multiforme is counter regulated by TRPM7 activity induced by exogenous ATP. ONCOTARGET, 2017.

                  Mostafa, H, Pala, A., Hoegel, J, Hlavac, M, Dietrich, E, Westhoff, AM, Nonnenmacher, L, Burster, T, Georgieff, M, Wirtz, CR, Schneider, EM. Immune phenotypes predict survival in patients with glioblastoma multiforme. J Hematol Oncol. 2016; Sep 1;9(1):77. doi: 10.1186/s13045-016-0272-3.

                  Persistent Treatment Resistant Lyme Borreliosis (pLB)

                  References:

                  Hein, T, Sander, P, Giryes, A., Reinhardt, J-O, Schneider, EM. Cytokine expression patterns and single nucleotide polymorphisms (SNPs) in patients with chronic borreliosis. Antibiotics 8:107 doi: 10.3390/antibiotics8030107

                  Diagnostic parameters and procedures

                  Shipping Material to our Laboratory

                  If you wish to send us material to perform diagnostics, please use the request sheet below.

                  Request Sheet (English)

                  Request Sheet (German)

                  Biomarkers

                  Cytokine concentrations in Plasma / CSF / Ascites indicate state of disease.
                  Surface marker phenotypes (FACS analysis) on white cells assist diagnostic accuracy.
                  In HLH (Hemophagocytic Lymphohistiocytosis) and MAS (Macrophage activation syndrome), NK (Natural Killer) cell function is impaired or NK-effector cells are significantly diminished.

                  Plasma biomarkers for inflammatory diseases

                  Results sheet of a healthy donor (example)

                  Immune Phenotypes

                  Phenotype analysis for inflammatory diseases

                  Example of a healthy donor (flow cytometry)

                  Whole Blood Stimulation for inflammatory and infectious diseases

                  Procedure

                  Research Application

                  Patients / Clinical Study Application

                  Examples of a clinical study

                  Examples of results obtained by TLRstimulation using TruCultures. IL-1ß release by healthy donors differs from patients with trauma or sepsis. Results have been presented at the TSIS 2010 meeting1.

                  1 Bindja J., Weiss M.E., Schmolz M., Stein G.M., Mapes J., Schneiderhan-Marra N., Joos J.O., Schneider E.M. Synthetic ligands against TLR2-9 in TruCultureTM - whole blood assays distinguish clinical stages of SIRS (trauma) and sepsis. Medimont Press, Proceedings Trauma, Shock, Inflammation and Sepsis, (2010) 55-63.

                  Whole blood phagocytosis assay

                  Using Eos-FP transfected E. coli, we provide an in-vitro phagocytosis assay to quantify the phagocytic activities of granulocytes and monocytes in whole blood and simulatenously monitor the phagosome-lysosome fusion process as described, previously (Schreiner et al. 2011); for more information see also (Dreschers et al. 2013 and Wiedenmann et al. 2004).

                  Literature:

                  Schreiner L, Huber-Lang, M, Weiss, ME, Hohmann, H, Schmolz, M., Schneider, EM. Phagocytosis and digestion of pH-sensitive fluorescent dye (Eos-FP) transfected E. coli in whole blood assays from patients with severe sepsis and septic shock. Journal of Cell Communication and Signaling. 2011, 5:139-144.

                  Dreschers, S., et al. Infection-induced bystander-apoptosis of monocytes is TNF-alpha-mediated. PLoS One8, e53589.

                  Wiedenmann, J., et al. EosFP, a fluorescent marker protein with UV-inducible green-to-red fluorescence conversion. Proc Natl Acad Sci U S A101, 15905-15910 (2004).

                  Research

                  ... focuses on the development of biomarker protocols for immune-based diagnostics in inflammatory diseases. She holds a data base of >20,000 patients with immune phenotypes and cytokine expression patterns, and functional SNPs. Biological materials such as PBMC, plasma, DNA, RNA are archived. Teaching concentrates on practical courses in Immunology, SNP sequencing and ex-vivo modeling of disease states for students in Molecular and Human Medicine.

                  MOODSTRATIFICATION

                  Since 2018, we are working on the MOODSTRATIFICATION EU project, representing one of 12 international partners.

                  https://moodstratification.eu/

                  The major aim of MOODSTRATIFICATION is to identify as well as to stratify immune signatures in patients with chronic psychiatric diseases. We concentrate on microRNA (miRNA) profiling as a new signature for psychosis.

                  As part of a clinical study conducted among members of the MOODSTRATIFICATION consortium (Horizon 2020, https://www.horizont2020.de/) we enrich extracellular vesicles (EVs) from cerebrospinal fluid (CSF) for miRNA isolation. Moreover, EVs are characterized by ZetaView® and flow cytometry.

                  Immune phenotypes are determined from peripheral blood in analogy to tumor- and sepsis-associated profiles.

                  Extracellular vesicles (EVs)

                  Upon stimulation with triggers such as ATP, macrophages release EVs (Fig. 1) which may fuse with specific target tissues, representing a communication axis between the peripheral and central (brain) immune system. Analyzing the content of released EVs, one can derive an outlook at the current individual immune state. After collecting EVs by ultracentrifugation, we analyze their content with main focus on microRNAs (miRNAs) as a new class of biomarkers.

                  MicroRNA profiling

                  Preliminary results led us to concentrate on hsa-miR-146a (guiding Myd88-TRAF6-IRAK-4 stimulation) and hsa-miR-21 related to inflammation as well hypoxia-induced pathways.

                  An extended miRNA panel includes hsa-miR-155, hsv1-miR-H2 and hsv1-miR-H27 aiming at the selective involvement of HSV-1 in psychiatric diseases.

                  Results will be compared with CSF from patients with subarachnoidal bleeding (study ID: 021-07122010).

                  Figure 2 shows an example of EVs isolated from CSF and Figure 3 shows results of our miRNA profiling results.

                  Collaborations:

                  • Prof. Dr. med. em. Karl Bechter (Klinik für Psychiatrie und Psychotherapie II (Günzburg), Universität Ulm) MOODSTRATIFICATION
                  • Prof. Dr. med. Thomas Becker (Klinik für Psychiatrie und Psychotherapie II (Günzburg), Universität Ulm) MOODSTRATIFICATION
                  • Paulo J. G. Kling Lourenço (Klinik für Psychiatrie und Psychotherapie II (Günzburg), Universität Ulm) MOODSTRATIFICATION
                  • Dr. H. C. Klein (Faculty of Medical Sciences, Academic Centre of Psychiatry, Universiteit Groningen, The Netherlands) Virus reactivation and replication in psychiatric patients; HSV-1-derived miRNA profiling
                  • Dr. Alexander Karabatsiakis (Klinische und Biologische Psychologie, Institut für Psychologie, Universität Innsbruck A-6020 Innsbruck) Mitochondrial respiratory assays
                  • Prof. Dr. med. Thomas Kapapa (Klinik für Neurochirurgie, Universitätsklinikum Ulm)

                  Hemophagocytosis by Antigen-Presenting Cells

                  Hemophagocytic Cells in HLH

                  The electron micrograph shows hemophagocytic cells during (A) and after (B) ingesting streptavidin-coated iron beads. Histiocytic progenitors were isolated from the lymphocyte fraction of the peripheral blood of a patient with acute HLH following Ficoll separation. Iron-containing beads of precisely 5 μm in diameter are rapidly phagocytosed (at a rate of roughly 10 min/bead). Histiocytes ingest a non-physiologic quantity of particles, causing massive cell enlargement and loss of surface membrane veils (arrow, A). No apoptosis occurs following phagocytosis, as can be identified from the structure of the nucleus in B. m, mitochondria.

                  (Schneider EM, Lorenz I, Walther P, Janka-Schaub GE. Natural killer deficiency: A minor or major factor in the manifestation of hemophagocytic lymphohistiocytosis? J Pediatr Hematol Oncol 25(9):680-683, 2003.)

                  In-Vitro Hemophagocytosis

                  Ficoll-isolated peripheral blood or bone marrow derived mononuclear cells from patients with HLH are depleted from non-adherent cells by plastic adherence.  Within 2-14 days these cultures give rise to a homogeneous population of large, floating cells with a pleomorphic morphology (Fig. 1), prominent signs of autophagy, and an immature dendritic cell phenotype1. Even after 21 days of in vitro culture, residual blood cells can be detected in cultured hemophagocytes1 (Fig. 2). Cultured hemophagocytes can be membrane-stained using fluorescent dyes and tested for their interaction with NK effectors such as NK-92 cells2. Figure 3 shows that such membrane-stained NK92 (red dye) interact with cultured hemophagocytes of a patient with HLH and shortly after cell-cell contact, the NK-effectors are phagocytozed by the hemophagocyte (stained with a green membrane-dye). The phagocytic activities of such cultured hemophagocytes derived from cultures of different patients with HLH vary:  Some hemophagocytes ingest NK-92 within minutes and accumulate more than 10 NK-92 cells per hemophagocyte.

                  Current research activites concentrate on the analysis of the hemophagocytic specifcities of hemophagocytes derived from individual patients with HLH.

                  Legends:

                  Figure 1:
                  Phase contrast of cultured hemophagocyte, floating, pleomorphic morphology and veiled surface structure.


                  Figure 2:
                  Structural features of hemophagocytes. Hemophagocytes with ingested and partially digested erythrocytes (arrows) located in a distal phagosome (HLH, chemical fixation). (A). Early hemophagocytosis of another autologous hemophagocyte with remarkable autophagous vacuoles (HLH, chemical fixation) (B). Hemophagocytosis of a hemophagocyte (HLH, chemical fixation) (C). More advanced state of erythrocyte digestion in a phagosome being engulfed by another autophagosome (HLH, chemical fixation) (D). As in C, a more advanced state of phagocytosis and digestion (sepsis, chemical fixation) (E).


                  Figure 3:
                  3a shows contact formation between NK-92 (red) and hemophagocyte (green)

                  3b shows early hemophagocytosis of NK-92 and another NK-92 forming contact

                  3c shows completed phagocytosis of one NK-92 and several other NK-92 cells forming contact

                  References:

                  1. Schneider, E., Lorenz, M, Walther, P Autophagy as a hallmark of hemophagocytic diseases. Vol. Chapter  3 (ed. Gorbunov. Nikolai (eds.), i.A.P., Regulation and Roles in Disease" ) (Nova Science Publishers, Inc.,   Cell Biology Research Progress, e-book, 2012).
                  2. Yan, Y., et al. Antileukemia activity of a natural killer cell line against human leukemias. Clin Cancer Res 4, 2859-2868 (1998).

                  Microparticles

                  Under Construction

                  We are sorry for the inconvenience.

                  Cellular Cytotoxicity

                  Under Construction

                  We are sorry for the inconvenience.

                  Teaching

                  Degree program: Molecular Medicine (Bachelor)

                  Internship Immunology; Part IV (4 weeks; description part I, part II)

                  Degree program: Molecular Medicine (Master)

                  Schedule blocks (each 4-5 weeks, detailed description is in progress):  

                  • “Infectious Diseases and Immune Defense” / “Trauma Research and Regenerative Medicine”
                  • “Infectious Diseases and Immune Defense” jeweils 4-5 Wochen (Beschreibung wird noch erstellt).

                  Some publications

                  Book Chapters

                  Sander, P, Walther, P, Moepps, B, Hinz, M, Mostafa, H, Schaefer, P, Pala, A, Wirtz, CR, Georgieff, M, and Schneider, EM. 2019. Mitophagy-Related Cell Death Mediated by Vacquinol-1 and TRPM7 Blockade in Glioblastoma IV. In: OMERHODZIC, I. & ARNAUTOVIĆ, K. (eds.) Glioma - Contemporary Diagnostics and Therapeutic Approaches. IntechOpen, 81-93.

                  Schneider, E.M., Lorenz, M.R., Walther, P. Autophagy  as a hallmark of hemophagocytic diseases. In „Autophagy in Health and Diseases.“ (N. V. Gorbunov (ed.) NOVA Publishers N.Y. 2011.

                  Bruecker UB, Schneider, EM. Microarrays in der experimentellen und klinischen Forschung. In: Chirurgische Forschung; 2005, p. 304-316. Krukemeyer, MG, Spiegel, H-U (eds);Thieme Verlag, Stuttgart, New York, ISBN: 3-13-133661-7

                  Janka-Schaub, G., Schneider, EM. Hämophagozytische Lymphohistiozytosen. In: Pädiatrische Hämatologie und Onkologie, 2005, p231-236. Gadner, H, Gaedicke, G, Niemeyer, C, Ritter, J (eds); Springer Verlag, Heidelberg, ISBN 13 978-3-540-03702-6
                   

                  Relevant publications, and /or products, services

                  Fischer, J.C., Zänker, K., van Griensven, M. et al. The role of passive immunization in the age of SARS-CoV-2: an update. Eur J Med Res 25, 16 (2020). https://doi.org/10.1186/s40001-020-00414-5

                  Matuschek, C., Fischer, J.C., Combs, S.E. et al. Measures of infection prevention and incidence of SARS-CoV-2 infections in cancer patients undergoing radiotherapy in Germany, Austria and Switzerland. Strahlenther Onkol (2020). https://doi.org/10.1007/s00066-020-01681-1

                  Matuschek, C., Moll, F., Fangerau, H. et al. Face masks: benefits and risks during the COVID-19 crisis. Eur J Med Res 25, 32 (2020). https://doi.org/10.1186/s40001-020-00430-5

                  Matuschek, C., Moll, F., Fangerau, H. et al. The history and value of face masks. Eur J Med Res 25, 23 (2020). https://doi.org/10.1186/s40001-020-00423-4

                  Gesundheit B, Ben-David E, Posen Y. Ellis R, , Wollmann G, Schneider  EM, Aigner,K,  Brauns, L, Nesselhut T, Ackva I,  Weisslein C,  Thaller A. Effective Treatment of Glioblastoma Multiforme with Oncolytic Virotherapy: A Case-Series. Frontiers in Oncology, section Cancer Molecular Targets and Therapeutics in press 2020.   Manuscript ID: 521092

                  Hein, T, Sander, P, Giryes, A., Reinhardt, J-O, Schneider, EM. Cytokine expression patterns and single nucleotide polymorphisms (SNPs) in patients with chronic borreliosis. Antibiotics 8:107 (2019) doi: 10.3390/antibiotics8030107

                  Denzinger, M, Staendker, L, Ehlers, K, Schneider, JM, Schulz, T, Hein, T, Wiese, S,  Roecker, A, Gross, R, Muench, J,  Bracht, H, Barth, E, Weiss, M, Georgieff, M,  Schneider, EM. Bioassay for Endothelial Damage Mediators Retrieved by Hemoadsorption, Sci Rep. Sci Rep 9, 14522 (2019) doi:10.1038/s41598-019-50517-1.

                  Walther P, Bauer A, Wenske N, Catanese A, Garrido D, Schneider EM. (2018) STEM tomography of high-pressure frozen and freeze-substituted cells: a comparison of image stacks obtained at 200 kV or 300 kV. Histochem Cell Biol. 2018 Sep 18. doi: 10.1007/s00418-018-1727-0. [Epub ahead of print]

                  Mack, A, Pfeiffer, C, Schneider, EM, Bechter, K. Schizophrenia or Atypical Lupus Erythematosus with Predominant Psychiatric Manifestations over 25 Years: Case Analysis and Review. Front Psychiatry. 2017 Jul 27;8:131. doi: 10.3389/fpsyt.2017.00131. eCollection 2017.

                  Waqas, SF, Hassnain, Hoang, AC, Lin, Y-T, Ampem, G., Azegrouz, H, Balogh, L, Thuróczy, J, Chen, J-C, Gerling, IC, Nam, S, Lim, J-S, Martínez-Ibañez, J, Real, J, Paschke, S, Quillet, R, Ayachi, S, Simonin, F, Schneider, EM, Brinkman, JA, Lamming, DW, Seroogy, CM, Röszer, T. Neuropeptide-FF increases M2 activation and self-renewal of adipose tissue macrophages. J Clin Investigation 2017 Jun 30;127(7):2842-2854. doi: 10.1172/JCI90152. Epub 2017 Jun 5. PubMed PMID: 28581443.

                  Current and previous projects or activities

                  • EU LSH-2003-1.1.0-1 QuAGSiC “Quantitative Analysis of Genes in Single Cells” EU FP6 07.2006 – 05-2008). This Project exemplified, how infectious agents can be identified in single cells of patients with different diseases using single cell PCR. Chronic infections with intracellular pathogens play a major role ijn autoimmune dysfunction syndromes.
                  • EU LSH-2003-1. 1.0-1 GenOSept “Genetics of sepsis in Europe” (EU FP6 03. 2005 – 02. 2008) Col. Functional single nucleotide polymorphisms (SNPs) play a major role in all kinds of inflammatory syndromes, the “Genetics in Sepsis “ project tought us the tools to address SNPs in autoimmune dysregulation of many other diseases, which we now follow in juvelnile rheumatoid arthritis as well as multiple sclerosis. The latter disease is most often linked to persistent borreliosis (pLB), Chlamydia, Yersinia, Rickettsia and other intracellular pathogens in addition to the preference of defined, polymorphic HLA antigens and SNPs in inflammatory cytokines such as TNF-α.
                  • H2020-SC1-2016-2017: SC1-PM-02-2017 (MOODSTRATIFICATION)  Immune Signatures for Therapy Stratification in Major Mood Disorders. Within this project, immune signatures of patients with psychosis are recruited and studied for pathogen vs. autoimmune characteristics. The cytokine and cell profiling is performed in peripheral blood ans well as in cerebrospinal fluid (CSF).
                  • Collaborative Project with Stephen Fuller (Department of Intensive Care Medicine, Nepean Hospital Clinical School, Univ. Sydney, Australia) and Marek Nalos (Medical ICU, Pilzen, Czech Republic) on P2X7 SNPs in survivors and non-survivors with sepsis and septic shock.
                  • Nanoparticle based therapeutics in fungal infections (John Luong and Jeremy D Glennon, Cork Univ. College, School of Chemistry, Ireland.
                  • VirA  WIDESPREAD-05-2020 CSA: Reducing networking gaps between Rīga Stradiņš University (RSU) and internationally – leading counterparts in viral infection-induced autoimmunity research”
                    Major impact and work in Ulm addresses the IMMUNOLOGY PLATFORM undergraduate and graduate students managements and knowledge dissemination using approproiate materials of autoimmune diseases related to viral infections. Project duration: Dec. 2020 – Dec 2023

                  Significant infrastructure / technical equipment

                  The Division of Experimental Anesthesiology is a fully equipped immunological laboratory, including access to mass spectroscopy, electron microscopy and single cell analysis, as well as patients’ records and material from a full spectrum of diseases with autoimmune disorders all collected in clinical studies. Archived material of viable cells, plasma and DNA is available from more than 20,000 individuals. Confocal microscopy, chemiluminescence based ELISA, qPCR, microparticle enrichment and characterization, following inflammasome activation are important tools to study autoimmune diseases and neurological disorders including PTSD. An ongoing study performed within the MOODSTRATIFICATION project addresses autoimmune dysfunction in patients with psychosis and a possible involvement of HSV1. The cell types in focus are monocytes (M1, M2), dendritic cells and naïve and different memory T lymphocytes.

                  Operational capacity

                  Is sufficient to cooperate on national as well as international in scientific and technical and mathematical projects.

                  Collaborations

                  • Dr. Thomas Joos,Dr. Nicole Schneiderhahn-Marra(Naturwissenschaftlich Medizinisches Institut Reutlingen, Universität Tübingen) „Clustering of Cytokinexpression patterns in patients with Trauma, Sepsis and Shock“. Peptide Ligand Assay develoments (Cathelicidines, defensins).
                  • Dr. Manfred Schmolz(Hotscreen GmbH, Reutlingen, Germany) Application and further developement of ex-vivo whole blood assays, TruCulture®.
                  • Prof. Dr. Knut M. Wittkowski (Rockefeller University, Center for Clinical and Translational Science (CCTS), N.Y., USA) Biomarker-based clinical scores, genome wide association studies.
                  • Kim, Hyung-Suk (NIH/NINR USA,  Bethesda, USA) GWAS in fibromyalgia.
                  • Dr. Sandeep Kumar Vashist (Global IVD Director at Pictor Biotechnology, Auckland, New Zea Land) Development of PoC devices.
                  • Prof. Dr. Hsin-Yun HSU (Department of Applied Chemistry/Institute of Molecular Science National Chiao; Tung University,  Hsinchu 30010, Taiwan) Carbon nanotubes in immature dendritic cells.